Lexaria Bioscience Corp (LEXX)

Apr 05, 2025

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully - Yahoo Finance

Apr 05, 2025

Apr 05, 2025

HighTower Advisors LLC Boosts Holdings in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World

Apr 05, 2025

Apr 03, 2025

Lexaria Completes Enrollment for Pioneering Drug Delivery Study - TipRanks

Apr 03, 2025

Apr 03, 2025

Lexaria completes enrollment for diabetes drug study - Investing.com

Apr 03, 2025

Apr 03, 2025

Lexaria completes enrollment for diabetes drug study By Investing.com - Investing.com UK

Apr 03, 2025

Apr 03, 2025

Lexaria's GLP-1 Study Hits Major Milestone with 20% Higher Patient Enrollment - Stock Titan

Apr 03, 2025

Apr 02, 2025

Lexaria begins human trial for oral diabetes treatment - Investing.com India

Apr 02, 2025

Apr 02, 2025

Lexaria begins human trial for oral diabetes treatment By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

Lexaria Bioscience Begins Human Trials for Oral Liraglutide Alternative - TipRanks

Apr 02, 2025

Apr 02, 2025

Lexaria's Human GLP-1 Study #5 Begins Dosing - TradingView

Apr 02, 2025

Apr 02, 2025

Revolutionary Oral GLP-1 Drug Challenges $1.8B Saxenda Market in New Trial - Stock Titan

Apr 02, 2025

Apr 01, 2025

Lexaria Bioscience (LEXX) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Apr 01, 2025

Mar 18, 2025

Oral tirzepatide capsules match injection efficacy in Lexaria study By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 18, 2025

Lexaria’s Oral Capsules Rival Injectable Weight Loss Treatment - TipRanks

Mar 18, 2025

Mar 18, 2025

Oral tirzepatide capsules match injection efficacy in Lexaria study - Investing.com

Mar 18, 2025

Mar 18, 2025

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R) - ACCESS Newswire

Mar 18, 2025

Mar 18, 2025

Lexaria Bioscience's (LEXX) DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound - StreetInsider.com

Mar 18, 2025

Mar 18, 2025

Revolutionary Oral Alternative to Zepbound Shows 47% Fewer Side Effects in Clinical Trial - StockTitan

Mar 18, 2025

Mar 04, 2025

Lexaria Bioscience stock hits 52-week low at $1.37 By Investing.com - Investing.com Australia

Mar 04, 2025

Mar 03, 2025

Lexaria Bioscience stock hits 52-week low at $1.37 - Investing.com

Mar 03, 2025

Feb 27, 2025

Lexaria Bioscience Advances Strategy in GLP-1 Drug Sector - TipRanks

Feb 27, 2025

Feb 27, 2025

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience - TradingView

Feb 27, 2025

Feb 27, 2025

Could This Small Biotech Solve GLP-1 Drugs' Biggest Problems? Lexaria's Triple Strategy Explained - StockTitan

Feb 27, 2025

Feb 24, 2025

Lexaria Bioscience Advances GLP-1 Study with New Ethics Approval - TipRanks

Feb 24, 2025

Feb 24, 2025

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm - TradingView

Feb 24, 2025

Feb 24, 2025

Can This Small Biotech Transform GLP-1 Drugs From Shots to Pills? Clinical Trial Update - StockTitan

Feb 24, 2025

Feb 20, 2025

Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication - TipRanks

Feb 20, 2025

Feb 20, 2025

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide - WICZ

Feb 20, 2025

Feb 20, 2025

Can This Small Biotech Revolutionize $30B GLP-1 Market With First-Ever Oral Liraglutide? - StockTitan

Feb 20, 2025

Feb 17, 2025

Lexaria Bioscience Corp. (NASDAQ:LEXX) Sees Significant Decline in Short Interest - Defense World

Feb 17, 2025

Feb 14, 2025

Lexaria Bioscience stock hits 52-week low at $1.62 - MSN

Feb 14, 2025

Feb 13, 2025

Lexaria Secures Two New Patents for Epilepsy Treatment with DehydraTECH - MSN

Feb 13, 2025

Feb 12, 2025

Lexaria secures new patents for epilepsy treatment tech By Investing.com - Investing.com Nigeria

Feb 12, 2025

Feb 11, 2025

Lexaria Bioscience stock hits 52-week low at $1.62 By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 11, 2025

Lexaria secures new patents for epilepsy treatment tech - MSN

Feb 11, 2025

Feb 11, 2025

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy - WICZ

Feb 11, 2025

Feb 11, 2025

Lexaria's Game-Changing Epilepsy Patents Outperform Epidiolex Technology | LEXX - StockTitan

Feb 11, 2025

Feb 06, 2025

Lexaria Initiates Groundbreaking Biodistribution Study for DehydraTECH GLP-1 - TipRanks

Feb 06, 2025

Feb 06, 2025

Revolutionary GLP-1 Study: Lexaria's DehydraTECH Goes Head-to-Head with Rybelsus - StockTitan

Feb 06, 2025

Feb 06, 2025

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway | Users | observernewsonline.com - FinancialContent

Feb 06, 2025

Feb 05, 2025

Lexaria Advances Human Study on Diabetes and Weight Loss Treatment - TipRanks

Feb 05, 2025

Feb 05, 2025

Revolutionary GLP-1 Breakthrough: Lexaria's Technology Matches Zepbound Efficacy with Fewer Side Effects - StockTitan

Feb 05, 2025

Jan 31, 2025

Lexaria reports promising drug delivery study results - Investing.com India

Jan 31, 2025

Jan 31, 2025

Research Analysts Issue Forecasts for LEXX Q2 Earnings - Defense World

Jan 31, 2025

Jan 30, 2025

Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024 - TipRanks

Jan 30, 2025

Jan 30, 2025

Lexaria Releases Annual Letter from the CEO - WICZ

Jan 30, 2025